abp688

ABP688 is a highly selective and noncompetitive antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5). It is primarily used as a radiolabeled positron emission tomography (PET) ligand—most commonly in its carbon-11 labeled form ([11C]ABP688)—to quantify mGluR5 receptor availability in the brain. ABP688 readily crosses the blood-brain barrier and binds specifically to mGluR5-rich regions. It has been utilized in clinical research to investigate neurological and psychiatric conditions such as Alzheimer's disease, major depressive disorder, chronic neuropathic pain, anxiety disorders, epilepsy, and for studying glutamatergic network alterations during epileptogenesis[1][2][3][4][7][8]. The compound was originally developed by Novartis.

Other names

3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-methyl-oxime